ECSP10010346A - Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis - Google Patents

Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis

Info

Publication number
ECSP10010346A
ECSP10010346A EC2010010346A ECSP10010346A ECSP10010346A EC SP10010346 A ECSP10010346 A EC SP10010346A EC 2010010346 A EC2010010346 A EC 2010010346A EC SP10010346 A ECSP10010346 A EC SP10010346A EC SP10010346 A ECSP10010346 A EC SP10010346A
Authority
EC
Ecuador
Prior art keywords
quinasa
triazolo
compounds
mtor
inhibitors
Prior art date
Application number
EC2010010346A
Other languages
English (en)
Inventor
Christoph Dehnhardt
Aranapakam Mudumbai Venkatesan
Los Santos Efren Guillermo De
Arie Zask
Semiramis Ayral-Kaloustian
Santos Osvaldo Dos
Zecheng Chen
Natasja Brooijmans
Jeroen Cunera Verheijen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of ECSP10010346A publication Critical patent/ECSP10010346A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a compuestos de 3H-[1,2,3]triazolo[4,5-d]pirimidina de Fórmula 1: 1o a una sal farmacéuticamente aceptable de los mismos, en la que las variables constituyentes son como se definen en el presente documento, a composiciones que comprenden los compuestos y a procedimientos para fabricar y usar los compuestos.
EC2010010346A 2008-01-15 2010-07-15 Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis ECSP10010346A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2108408P 2008-01-15 2008-01-15
US3468008P 2008-03-07 2008-03-07

Publications (1)

Publication Number Publication Date
ECSP10010346A true ECSP10010346A (es) 2010-08-31

Family

ID=40377318

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010346A ECSP10010346A (es) 2008-01-15 2010-07-15 Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis

Country Status (21)

Country Link
US (1) US20090181963A1 (es)
EP (1) EP2252296A1 (es)
JP (1) JP2011510010A (es)
KR (1) KR20100113567A (es)
CN (1) CN102014914A (es)
AP (1) AP2010005346A0 (es)
AU (1) AU2009205501A1 (es)
BR (1) BRPI0906519A2 (es)
CA (1) CA2712267A1 (es)
CO (1) CO6321259A2 (es)
CR (1) CR11568A (es)
DO (1) DOP2010000217A (es)
EA (1) EA201001017A1 (es)
EC (1) ECSP10010346A (es)
IL (1) IL206820A0 (es)
MA (1) MA32341B1 (es)
MX (1) MX2010007746A (es)
NI (1) NI201000119A (es)
SV (1) SV2010003621A (es)
WO (1) WO2009091788A1 (es)
ZA (2) ZA201004603B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
US20110053907A1 (en) * 2008-03-27 2011-03-03 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
NZ595372A (en) 2009-03-27 2013-11-29 Vetdc Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CN102480961A (zh) * 2009-06-24 2012-05-30 健泰科生物技术公司 与含氧杂环稠合的嘧啶化合物、组合物和使用方法
TW201105662A (en) * 2009-07-07 2011-02-16 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
BR112012019459A2 (pt) 2010-02-03 2017-10-17 Signal Pharm Llc identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
EA022623B1 (ru) 2010-10-06 2016-02-29 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные бензимидазола в качестве ингибиторов pi3-киназ
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
US20140303172A1 (en) * 2011-11-01 2014-10-09 Exelixis, Inc. Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies
US9499561B2 (en) 2012-04-10 2016-11-22 Shanghai Yingli Pharmaceutical Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
KR101761464B1 (ko) 2012-05-23 2017-07-25 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
BR112015026021A2 (pt) 2013-04-17 2017-07-25 Signal Pharm Llc terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
WO2014172432A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
TW201527300A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－***－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法
WO2014172426A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
MX2015014589A (es) 2013-04-17 2016-04-25 Signal Pharm Llc Tratamiento de cancer con dihidropirazino-pirazinas.
EA029072B1 (ru) 2013-04-17 2018-02-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
JP6441910B2 (ja) * 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
AP2016009562A0 (en) 2014-05-14 2016-11-30 Pfizer Pyrazolopyridines and pyrazolopyrimidines
WO2017087818A1 (en) * 2015-11-19 2017-05-26 The Regents Of The University Of Michigan Dual src/p38 kinase inhibitor compounds and their use as therapeutic agents
AU2018271862B2 (en) 2017-05-23 2022-12-15 Mei Pharma, Inc. Combination therapy
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
CN110950868B (zh) * 2018-09-27 2022-05-13 苏州锐明新药研发有限公司 吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用
CN113549080B (zh) * 2021-08-27 2023-05-16 中国医学科学院放射医学研究所 一类1,2,3-三氮唑并嘧啶类化合物、其制备方法和用途
KR20240015978A (ko) 2022-07-28 2024-02-06 박수산 다층 수력 발전시스템

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1277738B1 (en) * 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives

Also Published As

Publication number Publication date
US20090181963A1 (en) 2009-07-16
EA201001017A1 (ru) 2011-02-28
BRPI0906519A2 (pt) 2015-07-14
MA32341B1 (fr) 2011-06-01
CO6321259A2 (es) 2011-09-20
ZA201004603B (en) 2011-03-30
CN102014914A (zh) 2011-04-13
AP2010005346A0 (en) 2010-08-31
AU2009205501A1 (en) 2009-07-23
JP2011510010A (ja) 2011-03-31
ZA201005793B (en) 2011-04-28
SV2010003621A (es) 2011-07-05
CA2712267A1 (en) 2009-07-23
WO2009091788A1 (en) 2009-07-23
MX2010007746A (es) 2010-08-18
EP2252296A1 (en) 2010-11-24
IL206820A0 (en) 2010-12-30
NI201000119A (es) 2011-05-04
DOP2010000217A (es) 2010-07-31
KR20100113567A (ko) 2010-10-21
CR11568A (es) 2010-08-11

Similar Documents

Publication Publication Date Title
ECSP10010346A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis
ECSP10010112A (es) Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
ECSP10010556A (es) Piridinas y pirazinas como inhibidores de pi3k
ECSP12011935A (es) Triazolopiridinas
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
ECSP088871A (es) Derivados de triazolopirazina
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
CU20140068A7 (es) Triazolopiridinas sustituidas
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
UY30327A1 (es) Nuevos compuestos ii
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
ECSP13013011A (es) Triazolopiridinas
ECSP12012338A (es) Triazolopiridinas sustituidas
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CR10199A (es) Derivados de benzimidazol
ECSP10010597A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos
CU20110108A7 (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
ECSP088153A (es) Nuevos derivados de piperidina
CU20100148A7 (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis
CU20080204A7 (es) Derivados de triazolopirazina
DOP2007000096A (es) Derivados de triazolopirazina